小児の肥満および代謝機能障害に関連するステアトス性肝疾患におけるグルカゴン類ペプチド-1受容体アゴニストの役割

Rahiya Rehman¹

¹Department of Pediatric Gastroenterology, Saint Louis University, Saint Louis, MO 63108, United States. rahiya.rehman@health.slu.edu.

World journal of clinical pediatrics

|August 29, 2025

まとめ

小児の肥満と代謝機能障害に関連した脂肪性肝疾患 (MASLD) は,健康上の懸念が高まっています. グルカゴン様ペプチド-1受容体アゴニストは,子供におけるこれらの症状の治療に有望である.

科学分野:

小児内分泌学
ヘパトロジー
代謝障害

背景:

小児の肥満は深刻な長期的な健康被害をもたらす流行病です
代謝機能障害に関連した脂肪酸性肝疾患 (MASLD) は,子どもと青少年においてますます多く診断され,しばしば肥満に関連しています.
この2つの状態は心臓血管と代謝の合併症に重大なリスクをもたらします.

研究の目的:

小児肥満とMASLDの関連性を調べる
小児肥満とMASLDの現在の治療戦略をレビューする.
若者におけるこれらの状態の管理におけるグルカゴン型ペプチド-1受容体アゴニストの新興する役割を調査する.

主な方法:

小児肥満とMASLDの病理生理学の文献レビュー.
小児肥満とMASLDの現在の治療ガイドラインの分析.
小児集団におけるグルカゴン様ペプチド-1受容体アゴニストに関する新興研究のレビュー.

主要な成果:

小児肥満とMASLDは共通の病理生理学的経路を持っています
小児肥満とMASLDの確立した治療法について論じられています.
グルカゴン類ペプチド-1受容体アゴニストは,肥満の管理に潜在的であり,小児のデータも限られているが,成人におけるMASLDに関する新たな証拠がある.

結論:

小児肥満とMASLDの早期介入は極めて重要です
グルカゴン類ペプチド-1受容体アゴニストは,小児肥満および潜在的にMASLDの治療への有望な道を示しています.
これらの薬剤の安全性と有効性を確立するために,小児科でのさらなる研究が必要である.

キーワード:

グルカゴンのようなペプチドグルカゴンのようなペプチド-1 メタボリック機能障害に関連した脂肪性肝疾患肥満小児科

さらに関連する動画

08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.8K

10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K

関連する概念動画

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:15

Hypoglycemia and Glucagon

334

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

334

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

288

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

288

01:28

Insulin: The Receptor and Signaling Pathways

1.5K

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...

1.5K

01:24

Overview of Lipid Metabolism

2.4K

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

2.4K

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

255

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

255

関連する実験動画